TY - JOUR
T1 - Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration
AU - Dasgupta, Swikriti
AU - Imamura, Michio
AU - Gorstein, Evan
AU - Nakahara, Takashi
AU - Tsuge, Masataka
AU - Churkin, Alexander
AU - Yardeni, David
AU - Etzion, Ohad
AU - Uprichard, Susan L.
AU - Barash, Danny
AU - Cotler, Scott J.
AU - Dahari, Harel
AU - Chayama, Kazuaki
N1 - Funding Information:
This work was supported by the Japan Agency for Medical Research and Development (grant 19fk0210020h0003) and the National Institutes of Health (grants R01AI078881 and R01GM121600).
Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions
PY - 2020/10/1
Y1 - 2020/10/1
N2 - We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.
AB - We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.
KW - Direct-acting antivirals
KW - Hepatitis C virus
KW - Mathematical modeling
KW - Response-guided therapy
UR - http://www.scopus.com/inward/record.url?scp=85087493478&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiaa219
DO - 10.1093/infdis/jiaa219
M3 - Article
C2 - 32363394
AN - SCOPUS:85087493478
VL - 222
SP - 1165
EP - 1169
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 7
ER -
